Held by 2 specialist biotech funds
# Signal Note: Eventide Initiates DOCS Position Eventide's $749K entry into Doximity—a healthcare SaaS platform with 80%+ physician penetration—signals conviction in digital health infrastructure plays amid accelerating provider digitalization. The position timing aligns with DOCS' expanding margins and recurring revenue model, which typically appeal to values-focused investors prioritizing sustainable business models over speculative pipelines. This represents a thematic pivot toward enabling platforms rather than drug-dependent exposure, potentially hedging biotech volatility while maintaining healthcare sector beta.